appropriate, acute care hospitals, dialysis facilities, 
nursing homes, ambulatory surgical centers, and 
other ambulatory health care settings in which anti-
microbial drugs are routinely prescribed. The Sec-
retary shall seek to collect such data from electronic 
medication administration reports and laboratory 
systems to produce the reports described in para-
graph (4). 
(4) PUBLIC AVAILABILITY OF DATA.—The Sec-
retary, acting through the Director of the Centers 
for Disease Control and Prevention, shall, for the 
purposes of improving the monitoring of important 
trends in patient outcomes in relation to anti-
bacterial resistance— 
(A) make the data derived from surveil-
lance under this subsection publicly available 
through reports issued on a regular basis that 
is not less than annually; and 
(B) examine opportunities to make such 
data available in near real time. 
SEC. 6. APPROPRIATIONS. 
(a) IN GENERAL.—To carry out this Act, there are 
hereby appropriated to the Secretary, out of amounts in 
the 
Treasury 
not 
otherwise 
appropriated, 
VerDate Sep 11 2014 
23:19 Dec 21, 2020
Jkt 019200
PO 00000
Frm 00035
Fmt 6652
Sfmt 6201
E:\BILLS\H8920.IH
H8920
kjohnson on DSK79L0C42PROD with BILLS
$11,000,000,000, for fiscal year 2021, to remain available 
until expended. 
(b) EMERGENCY DESIGNATION.— 
(1) IN
GENERAL.—The amounts provided by 
this section are designated as an emergency require-
ment pursuant to section 4(g) of the Statutory Pay- 
As-You-Go Act of 2010 (2 U.S.C. 933(g)). 
(2) DESIGNATION IN SENATE.—In the Senate, 
this section is designated as an emergency require-
ment pursuant to section 4112(a) of H. Con. Res. 
71 (115th Congress), the concurrent resolution on 
the budget for fiscal year 2018. 
SEC. 7. STUDIES AND REPORTS. 
(a) IN GENERAL.—Not later than 6 years after the 
date of enactment of this Act, the Comptroller General 
of the United States shall complete a study on the effec-
tiveness of this Act in developing priority antimicrobial 
drugs. Such study shall examine the indications for, usage 
of, development of resistance with respect to, and private 
and societal value of critical need antimicrobial drugs, and 
the impact of the programs under this Act on patients 
and markets of critical need antimicrobial drugs. The 
Comptroller General shall report to the Committee on 
Health, Education, Labor, and Pensions of the Senate and 
VerDate Sep 11 2014 
23:19 Dec 21, 2020
Jkt 019200
PO 00000
Frm 00036
Fmt 6652
Sfmt 6201
E:\BILLS\H8920.IH
H8920
kjohnson on DSK79L0C42PROD with BILLS
the Committee on Energy and Commerce of the House 
of Representatives on the findings of such study. 
(b) ANTIBIOTIC USE IN THE UNITED STATES; AN-
NUAL REPORTS.—The Director of the Centers for Disease 
Control and Prevention shall, each year, update the report 
entitled ‘‘Antibiotic Use in the United States’’ to include 
updated information on progress and opportunities with 
respect to data, programs, and resources for prescribers 
to promote appropriate use of antimicrobial drugs. 
(c) REPORTS
ON ANTIFUNGAL RESISTANCE
AND 
ANTIMICROBIAL PROPHYLACTICS.—Not later than 3 years 
after the date of enactment of this Act, the Director of 
the Centers for Disease Control and Prevention shall pub-
lish— 
(1) a report on antifungal resistance in the 
United States; and 
(2) a report on antimicrobial prophylactics. 
SEC. 8. DEFINITIONS. 
In this Act— 
(1) the term ‘‘antimicrobial drug’’— 
(A) subject to subparagraph (B), means— 
(i) an antibiotic drug, as defined in 
section 201(jj) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 321(jj)); or 
VerDate Sep 11 2014 
23:19 Dec 21, 2020
Jkt 019200
PO 00000
Frm 00037
Fmt 6652
Sfmt 6201
E:\BILLS\H8920.IH
H8920
kjohnson on DSK79L0C42PROD with BILLS
(ii) a biological product, as defined in 
section 351(i) of the Public Health Service 
Act (42 U.S.C. 262(i)), that exhibits anti-
microbial activity; and 
(B) excludes— 
(i) any antifungal drug; and 
(ii) any vaccine; 
(2) the term ‘‘Committee’’ means the Com-
mittee on Critical Need Antimicrobials established 
under section 2; and 
(3) the term ‘‘Secretary’’ means the Secretary 
of Health and Human Services. 
Æ 
VerDate Sep 11 2014 
23:19 Dec 21, 2020
Jkt 019200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6301
E:\BILLS\H8920.IH
H8920
kjohnson on DSK79L0C42PROD with BILLS